Memorial Sloan Kettering Cancer Center

Next-generation DNA sequencing (NGS) results for tumours from phase II ABRAZO study of talazoparib after platinum or cytotoxic non-platinum regimens in patients (pts) with advanced breast cancer (ABC) and germline BRCA1/2 (gBRCA) mutations (2019) Turner NC, Laird AD, Telli ML, Rugo HS, Mailliez A, Ettl J, Grischke EM, et al. Conference contribution RIG-I activation is critical for responsiveness to checkpoint blockade (2019) Heidegger S, Wintges A, Stritzke F, Bek S, Steiger K, Koenig PA, Goettert S, et al. Journal article Differentiation and tissue-adaptation of type-2 innate lymphoid cells during helminth infection (2019) Lian M, Zeis P, Fan X, Symowski C, Gentek R, Bajenoff M, Rudensky AY, et al. Conference contribution Image reconstruction for interrupted-beam x-ray CT on diagnostic clinical scanners (2019) Muckley MJ, Chen B, Vahle T, O'Donnell T, Knoll F, Sodickson AD, Sodickson DK, Otazo R Journal article Multicenter, International Assessment of the Eighth Edition of the American Joint Committee on Cancer Cancer Staging Manual for Conjunctival Melanoma (2019) Jain P, Finger PT, Damato B, Coupland SE, Heimann H, Kenawy N, Brouwer NJ, et al. Journal article The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells (2019) Mestermann K, Giavridis T, Weber J, Rydzek J, Frenz S, Nerreter T, Mades A, et al. Journal article International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders (2019) Hillengass J, Usmani S, Rajkumar SV, Durie BG, Mateos MV, Lonial S, Joao C, et al. Journal article, Review article A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO) (2019) Turner NC, Telli ML, Rugo HS, Mailliez A, Ettl J, Grischke EM, Mina LA, et al. Journal article Adverse events 2.0-Let us get SERIOs New reporting for adverse event outcomes needed in the era of immunooncology (2019) Heinzerling L, Ascierto PA, Dummer R, Gogas H, Grob JJ, Lebbe C, Long GV, et al. Journal article, Letter T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy (2019) Yamamoto TN, Lee PH, Vodnala SK, Gurusamy D, Kishton RJ, Yu Z, Eidizadeh A, et al. Journal article